All News

Triple-Class Refractory Myeloma Requires ‘Greater Attention to Symptoms'

March 24th 2022

To address symptoms from myeloma that is resistant to treatment, education and communication with care teams are key.

As Spring Breakers Break COVID-19 Precautions, I Found Inspiration in One Steadfast Young Man

March 24th 2022

Many young adults seem to be throwing caution to the wind with COVID-19 precautions, but a neighbor of mine gave me hope for the younger generations since he was steadfast in protecting vulnerable people like me.

Potential FDA Cancer Drug Approvals on the Horizon This Spring

March 24th 2022

The Food and Drug Administration plans on reviewing multiple new cancer therapies this spring.

Personalized Treatment Advanced the Field and Decreased Side Effects in Head and Neck Cancer

March 24th 2022

Over the last 20 years, head and neck cancer treatment moved away from aggressive treatments for all patients to a more personalized approach — improving both outcomes and quality of life for patients with the disease.

FDA Approves First PSMA-Targeted Therapy for Metastatic Castration-Resistant Prostate Cancer

March 23rd 2022

Patients with PSMA-positive metastatic castration-resistant prostate cancer can now be treated with Pluvicto, which may provide hope to an unmet need in this patient population.

Madeleine Albright, First Female Secretary of State and ‘Courageous Woman,’ Dies of Cancer

March 23rd 2022

Madeleine Albright, the first female secretary of state, died of cancer earlier today. She was 84 years old.

Intravenous and Direct-to-Abdomen Chemotherapy Plus Avastin Lead to Similar Outcomes in Advanced Ovarian Cancer

March 23rd 2022

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

‘I Would Have Given Up a Long Time Ago’ and Other Things Not to Say to Cancer Survivors

March 23rd 2022

My survivor friends and I share the insensitive comments we have received about our cancer diagnosis.

Treating Bone Pain in Multiple Myeloma

March 23rd 2022

Bone pain is a common symptom that patients with multiple myeloma face, but some may find relief with treatments and exercise.

Swapping Surgery for Adjuvant Therapy May Improve Outcomes in Patients With Stage 3 Melanoma

March 23rd 2022

Patients with stage 3 melanoma, a type of skin cancer, that has metastasized to the lymph nodes may benefit from skipping lymph node removal surgery and receiving treatment with adjuvant therapy, although more research is needed in this area.

Opdivo Plus Experimental Drug Combo Fails to Improve Survival, Response Rates in Patients With Advanced Melanoma

March 22nd 2022

The use of bempegaldesleukin and Opdivo failed to meet its goal of significantly improving progression-free survival and responses to treatment, compared with Opdivo alone in patients with previously untreated unresectable or metastatic melanoma, according to data from an initial analysis of the phase 3 PIVOT IO-001 study.

What Happens When a Patient Develops a Secondary Cancer Years After Undergoing Treatment?

March 22nd 2022

Although certain cancer treatments have been linked to an increased risk of a secondary cancer years later, an expert notes there are no genetic or pathologic studies that prove the association between new and previous cancers.

A Terrible Legacy to Pass Down: Inheriting Lynch Syndrome from an Abusive Parent

March 22nd 2022

My father was an alcoholic, and though he died in 1992, he lives on through my siblings and me because we all inherited a cancer syndrome from him.

Treatment With Novel Drug Induces Promising Response Rates in Ovarian Cancer Subgroup

March 22nd 2022

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

Zejula-Avastin Combo Improves Outcomes, With ‘No Impact on Quality of Life’ in High-Risk Ovarian Cancer

March 22nd 2022

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

FDA Approves Second Keytruda Indication for Subset of Advanced Endometrial Cancer

March 21st 2022

The FDA’s approval of Keytruda is indicated for patients with advanced endometrial carcinoma with specific genetic characteristics whose disease progressed after systemic therapy and are not suitable for surgery or radiation.

Depression and Anxiety Shown to Deter Patients With Cancer From Joining Clinical Trials

March 21st 2022

One of the hurdles, according to the study’s lead author, is that many patients with cancer are worried about receiving a placebo in a clinical trial.

After Forming a Bond With the Oncologist, We’re Hoping Our Goodbye Is Forever

March 21st 2022

Eventually, my daughter will stop seeing her oncologist, and while I appreciate all that he has done, I hope that they part ways forever.

20 Years of Advancements Brings a 'Luxury' of Treatment Options for Patients With Myeloma

March 21st 2022

In honor of CURE®’s 20th anniversary, we spoke with experts on how the past 20 years have revolutionized multiple myeloma treatment.

There’s No Denying Cancer Survivorship Is Hard, But We Can Get Through It

March 21st 2022

During my treatment for triple-negative breast cancer, there was a plan for every situation, but once I entered survivorship, I was in uncharted territory.

Some Immunity Is Better Than None Against COVID-19

March 20th 2022

Many things can influence a patient’s response to the COVID-19 vaccine, such as their treatments or whether they have a higher tumor burden.

After a Horrible Experience With a Prescribed Drug Taper, I Decided to Wean Off Prednisone Myself

March 19th 2022

I’d become an eating machine with a loathsome attitude on prednisone, so I decided to conduct my own taper of the drug.

Taking Cancer One Day — and One Outfit — at a Time

March 19th 2022

It can be difficult for patients to go about their daily life with this bone pain, so what can help?

FDA Approves Opdualag, a New Fixed-Dose Combination Treatment, For Certain Patients With Skin Cancer

March 19th 2022

The FDA’s decision to greenlight Opdualag is based on data that showed that the combination more than doubled survival without disease progression when compared with Opdivo in patients with previously untreated metastatic or unresectable melanoma, a type of skin cancer.

Trial to Assess Efficacy of Test to Detect Cancer Recurrence Across a Plethora of Solid Tumors Enrolls First Patient

March 18th 2022

Approximately 100,000 patients with stage 1 to stage 3 solid tumors will be enrolled onto the trial across 25 sites, according to the manufacturer of the test aimed at detecting cancer recurrence.

Why It’s Important to Collaborate Through Communication in Myeloma

March 18th 2022

As part of its “Speaking Out” video series, CURE® spoke with Throwing Bones founder Kenny Capps about the importance of patient-physician communication during a myeloma journey.

Not Everything Is ‘Fine,’ and That’s OK: A Guide on How I Wish to Be Supported Through Cancer

March 18th 2022

There’s a fine line between toxic positivity and encouragement. Myself and other cancer survivors know that all too well.

Actor William Hurt Dies of Prostate Cancer, Several Cancer Centers Establish Helpline to Connect Ukrainian Patients to Cancer Care and More

March 18th 2022

From two celebrity deaths due to cancer to leading American cancer organizations coming together to help patients with cancer fleeing Ukraine, here’s what’s happening in the cancer space this week.

Myeloma Survivor Is ‘Fighting Cancer One Outfit at a Time’

March 18th 2022

Donna McNutt uses her love of fashion to find confidence and motivation — and shares it with others — after a myeloma diagnosis.

FDA Clears The Way For a Trial to Evaluate an Investigational Drug Plus Keytruda in Treatment of Solid Tumors

March 17th 2022

The early-stage trial, according to the investigational drug’s manufacturer, Adagene, is expected to take place across multiple sites in the United States and Asia Pacific.